{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:09:30Z","timestamp":1761091770219,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":4307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2001,10]]},"DOI":"10.1053\/seiz.2001.0543","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T17:49:59Z","timestamp":1027878599000},"page":"525-529","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Visual fields and tiagabine: a quandary"],"prefix":"10.1053","volume":"10","author":[{"given":"Kenneth R","family":"Kaufman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick E","family":"Lepore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J","family":"Keyser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/seiz.2001.0543_RF1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"BMJ"},{"key":"10.1053\/seiz.2001.0543_RF2","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1212\/WNL.53.9.2082","article-title":"Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings","volume":"53","author":"Miller","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0543_RF3","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","article-title":"Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects","volume":"53","author":"Kalviainen","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0543_RF4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1034\/j.1600-0420.2000.078005580.x","article-title":"Visual field defects in patients taking vigabatrin","volume":"78","author":"Midelfart","year":"2000","journal-title":"Acta Ophthalmologica Scandinavica"},{"key":"10.1053\/seiz.2001.0543_RF5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/bjo.84.5.499","article-title":"A controlled study of vigabatrin and visual abnormalities","volume":"84","author":"Manuchehri","year":"2000","journal-title":"British Journal of Ophthalmology"},{"key":"10.1053\/seiz.2001.0543_RF6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","article-title":"Visual field defects associated with vigabatrin therapy","volume":"67","author":"Lawden","year":"1999","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1053\/seiz.2001.0543_RF7","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1528-1157.2000.tb00117.x","article-title":"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electrotinography in patients with vigabatrin-attributed visual field constriction","volume":"41","author":"Harding","year":"2000","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0543_RF8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(99)02095-4","article-title":"Reversibility of vigabatrin-induced visual-field defect","volume":"354","author":"Versino","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/seiz.2001.0543_RF9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1053\/seiz.2000.0397","article-title":"Recovery of visual field constriction following discontinuation of vigabatrin","volume":"9","author":"Krakow","year":"2000","journal-title":"Seizure"},{"key":"10.1053\/seiz.2001.0543_RF10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1212\/WNL.55.1.40","article-title":"Visual function loss from vigabatrin: effect of stopping the drug","volume":"55","author":"Johnson","year":"2000","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0543_RF11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0014-2999(77)90270-9","article-title":"Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic GABA and gamma-vinyl GABA, two irreversible GABA-T inhibitors","volume":"45","author":"Schechter","year":"1977","journal-title":"European Journal of Pharmacology"},{"key":"10.1053\/seiz.2001.0543_RF12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S1059-1311(96)80041-0","article-title":"Effects of tiagabine and vigabatrin on GABA uptake into primary cultures of rat cortical astrocytes","volume":"5","author":"Leach","year":"1996","journal-title":"Seizure"},{"key":"10.1053\/seiz.2001.0543_RF13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.50.3.614","article-title":"Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings","volume":"50","author":"Krauss","year":"1998","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0543_RF14","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0161-6420(99)90345-7","article-title":"Symptomatic and asymptomatic visual loss in patients taking vigabatrin","volume":"106","author":"Daneshvar","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1053\/seiz.2001.0543_RF15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1442-9071.1992.tb00952.x","article-title":"Diazepam and its effects on visual fields","volume":"20","author":"Elder","year":"1992","journal-title":"Australian and New Zealand Journal of Ophthalmology"},{"key":"10.1053\/seiz.2001.0543_RF16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0140-6736(05)79254-0","article-title":"Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic drugs","volume":"353","author":"Baulac","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/seiz.2001.0543_RF17","first-page":"418","article-title":"Concentric changes in the visual field associated with GABA-mimetic antiepileptic agents","volume":"22","author":"Nordmann","year":"1999","journal-title":"Journal Francais d'Ophthalmologie"},{"key":"10.1053\/seiz.2001.0543_RF18","first-page":"1694","article-title":"Severe persistent visual field constriction associated with vigabatrin. Patients taking vigabatrin should have regular visual field testing","volume":"314","author":"Blackwell","year":"1997","journal-title":"BMJ"},{"key":"10.1053\/seiz.2001.0543_RF19","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1212\/WNL.55.3.333","article-title":"Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants","volume":"55","author":"Miller","year":"2000","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0543_RF20","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0006-3223(99)00316-9","article-title":"Open-label adjunctive topiramate in the treatment of bipolar disorders","volume":"47","author":"McElroy","year":"2000","journal-title":"Biological Psychiatry"},{"key":"10.1053\/seiz.2001.0543_RF21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1034\/j.1600-0404.2000.0006a.x","article-title":"Gabapentin use in neuropathic pain syndromes","volume":"101","author":"Nicholson","year":"2000","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1053\/seiz.2001.0543_RF22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0165-0327(98)00198-0","article-title":"Open maintenance treatment of bipolar spectrum patients who responded to gabapentin augmentation in the acute phase of treatment","volume":"55","author":"Schaffer","year":"1999","journal-title":"Journal of Affective Disorders"},{"key":"10.1053\/seiz.2001.0543_RF23","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/10401239809147036","article-title":"Adjunctive tiagabine treatment of psychiatric disorders: three cases","volume":"10","author":"Kaufman","year":"1998","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1053\/seiz.2001.0543_RF24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(97)05035-6","article-title":"Tiagabine","volume":"351","author":"Leach","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/seiz.2001.0543_RF25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1053\/seiz.1999.0326","article-title":"Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study","volume":"8","author":"Sills","year":"1999","journal-title":"Seizure"},{"key":"10.1053\/seiz.2001.0543_RF26","first-page":"146","article-title":"Absence of visual field defects in patients taking tiagabine","volume":"39 (Suppl. 6)","author":"Collins","year":"1998","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0543_RF27","first-page":"6","article-title":"Visual field restriction with new antiepileptic medication","volume":"39 (Suppl. 2)","author":"Beran","year":"1998","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0543_RF28","first-page":"A249","article-title":"Predictability of visual field defects in patients exposed to GABAergic agents, vigabatrin, or tiagabine","volume":"52 (Suppl. 2)","author":"Beran","year":"1999","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0543_RF29","first-page":"A336","article-title":"Absence of concentric visual field defects in patients with long-term tiagabine monotherapy","volume":"52 (Suppl. 2)","author":"Kalviainen","year":"1999","journal-title":"Neurology"},{"year":"1994","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","key":"10.1053\/seiz.2001.0543_RF30"},{"key":"10.1053\/seiz.2001.0543_RF31","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(05)64979-3","article-title":"Lamotrigine and toxic epidermal necrolysis","volume":"348","author":"Wadelius","year":"1996","journal-title":"Lancet"},{"key":"10.1053\/seiz.2001.0543_RF32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1059-1311(98)80074-5","article-title":"Lamotrigine toxicity secondary to sertraline","volume":"7","author":"Kaufman","year":"1998","journal-title":"Seizure"},{"key":"10.1053\/seiz.2001.0543_RF33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000008051","article-title":"Assessment of colour vision in epileptic patients exposed to single-drug therapy","volume":"41","author":"Lopez","year":"1999","journal-title":"European Neurology"},{"key":"10.1053\/seiz.2001.0543_RF34","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0161-6420(00)00077-4","article-title":"Color vision in epileptic patients treated with vigabatrin or carbamazepine monotherapy","volume":"107","author":"Nousiainen","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1053\/seiz.2001.0543_RF35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0161-6420(95)31060-3","article-title":"Automated perimetry detects visual field loss before manual Goldmann perimetry","volume":"102","author":"Katz","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1053\/seiz.2001.0543_RF36","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1111\/j.1528-1157.1999.tb01599.x","article-title":"Characteristics of a unique visual field defect attributed to vigabatrin","volume":"40","author":"Wild","year":"1999","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0543_RF37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1212\/WNL.55.3.347","article-title":"Separating the retinal electrophysiologic effects of vigabatrin. Treatment versus field loss","volume":"55","author":"Harding","year":"2000","journal-title":"Neurology"},{"key":"10.1053\/seiz.2001.0543_RF38","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1528-1157.2000.tb00212.x","article-title":"Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication","volume":"41","author":"Hardus","year":"2000","journal-title":"Epilepsia"},{"key":"10.1053\/seiz.2001.0543_RF39","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/bmj.314.7095.1693a","article-title":"Severe persistent visual field constriction associated with vigabatrin. Reaction may be dose dependent","volume":"314","author":"Wong","year":"1997","journal-title":"BMJ"},{"key":"10.1053\/seiz.2001.0543_RF40","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1136\/bmj.320.7246.1403","article-title":"Visual field defect associated with vigabatrin: Method of estimating prevalence was inappropriate","volume":"320","author":"Manuchehri","year":"2000","journal-title":"BMJ"},{"key":"10.1053\/seiz.2001.0543_RF41","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/bmj.319.7218.1165","article-title":"Visual field defect associated with vigabatrin: observational cohort study","volume":"319","author":"Wilton","year":"1999","journal-title":"BMJ"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131101905436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131101905436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:23:02Z","timestamp":1761009782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131101905436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,10]]}},"alternative-id":["S1059131101905436"],"URL":"https:\/\/doi.org\/10.1053\/seiz.2001.0543","relation":{},"ISSN":["1059-1311"],"issn-type":[{"type":"print","value":"1059-1311"}],"subject":[],"published":{"date-parts":[[2001,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visual fields and tiagabine: a quandary","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/seiz.2001.0543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2001 BEA Trading, Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}